The function of inositol 1,4,5-trisphosphate receptors (IP3Rs) in the human heart is largely unknown and may have important implications in the modulation of myocardial performance and rhythm disturbances. IP3Rs may partly regulate the electric and mechanical properties of cardiomyocytes, contributing to the control of the electric stability and inotropic state of the myocardium. In this study, we have identified that IP3Rs are expressed and operative in nonfailing human left ventricular myocytes and are upregulated in failing human left ventricular myocytes. After Gαq-protein-coupled receptor activation, the Ca 2+ mobilized from the sarcoplasmic reticulum by IP3Rs contributes to the decrease in resting membrane potential, prolongation of the action potential, and incidence of early afterdepolarizations. Ca 2+ transient amplitude and myocyte shortening are enhanced, and extrasystolic and dysregulated Ca 2+ elevations and contractions are apparent. These defects in the electric and mechanical behavior of human cardiomyocytes result in increased developed tension and electric disorders of the myocardium. Thus, the Gαq-protein-coupled receptor/IP3R effector pathway offers inotropic reserve, which is hindered by electric instability and contractile abnormalities. See p 1286.
Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation
Elevated levels of both nonfasting remnant cholesterol and low-density lipoprotein cholesterol are causally associated with ischemic heart disease, but whether both lipoproteins also are associated with low-grade inflammation is unknown. This is a clinically important question because atherosclerosis is a disease with an inflammatory component and because randomized, clinical intervention trials have shown that statins prevent cardiovascular disease in individuals with low-grade inflammation with moderately elevated levels of C-reactive protein, even when low-density lipoprotein cholesterol levels are relatively low. The reason could be that statins lower not only low-density lipoprotein cholesterol levels but also triglycerides levels and thus remnant cholesterol levels. In this study, we found both elevated levels of nonfasting remnant cholesterol and elevated levels of low-density lipoprotein cholesterol to be causally associated with increased risk of ischemic heart disease, but only elevated levels of nonfasting remnant cholesterol were causally associated with low-grade inflammation. Taken together, this suggests that elevated low-density lipoprotein cholesterol levels cause atherosclerosis without a major inflammatory component, whereas an inflammatory component of atherosclerosis is driven by elevated nonfasting remnant cholesterol levels. Thus, we here point toward a new direction for reducing cardiovascular disease beyond that achieved through low-density lipoprotein cholesterol lowering. See p 1298.
Multiethnic Meta-Analysis of Genome-Wide Association Studies in >100 000 Subjects Identifies 23 Fibrinogen-Associated Loci but No Strong Evidence of a Causal Association Between Circulating Fibrinogen and Cardiovascular Disease
Plasma fibrinogen concentration is a predictor of cardiovascular disease independently of other traditional risk factors, and variation in fibrinogen concentration has a substantial heritable component. We conducted a meta-analysis of 28 genome-wide association studies, including >90 000 subjects of European ancestry and substantial numbers of blacks and Hispanics. We identified 24 genome-wide significant (P<5×10−8) independent single-nucleotide polymorphisms in 23 genetic loci, including 15 novel associations, together accounting for 3.7% of plasma fibrinogen variation. Gene-set enrichment analysis highlighted potential key roles in fibrinogen regulation for the known structural fibrinogen genes, as well as inflammation and other candidate pathways. However, in an evaluation for associations of the top fibrinogen single-nucleotide polymorphisms with coronary artery disease, stroke, and venous thromboembolism in very large case-control genome-wide studies, there was no evidence for association with any of these clinical outcomes of either the single single-nucleotide polymorphism most closely related to fibrinogen level (in the fibrinogen gene) or the combined effect of all 24 fibrinogen-associated single-nucleotide polymorphisms (across 23 distinct loci). Our findings in a very large total study population provide comprehensive data for new and known genetic variants underlying fibrinogen concentration in human populations, including multiple ethnic groups. Our findings highlight potential pathways for future study of the role of fibrinogen in the pathophysiology of atherosclerosis and cardiovascular disease. Clinical outcome analysis does not support a strong causal relationship between circulating levels of fibrinogen and coronary artery disease, stroke, or venous thromboembolism. See p 1310.
Effects of Visit-to-Visit Variability in Systolic Blood Pressure on Macrovascular and Microvascular Complications in Patients With Type 2 Diabetes Mellitus: The ADVANCE Trial
Elevated blood pressure (BP) is a modifiable risk factor for macrovascular diseases such as coronary heart disease and stroke, and microvascular complications of diabetes mellitus such as nephropathy and retinopathy. In the present analyses, we proved that visit-to-visit variability of systolic blood pressure (SBP), defined as the standard deviation or coefficient of variation during 24 months, was a significant risk factor for major macrovascular and microvascular complications of diabetes mellitus, and for all-cause mortality, as well, by using data from a large-scale randomized controlled trial of patients with type 2 diabetes mellitus, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE). These associations were independent of usual BP, defined as the mean SBP during the same period, and other cardiovascular risk factors and BP-lowering treatment. Similar associations were Volume 128 ◼ Number 12 ◼ September 17, 2013
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September 17, 2013 found for maximum SBP during the same period. Our findings suggest that the higher variability or maximum of SBP may be an important factor for the prediction of future vascular events and a potential therapeutic target, even in patients without hypertension. However, there are substantial gaps in our understanding of the best ways to apply this knowledge to the practical management of BP in patients with type 2 diabetes mellitus, and it remains uncertain how best to treat patients with type 2 diabetes mellitus who have high BP variability or maximum SBP. More work is needed to determine how to evaluate and treat the instability of BP in routine clinical practice. See p 1325.
Cost-Effectiveness of Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease and Abnormal Fractional Flow Reserve
The Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 2 Trial randomized patients with stable coronary artery disease and at least 1 stenosis with an abnormal fractional flow reserve to either percutaneous coronary intervention (PCI) or medical therapy alone. Patients randomized to PCI had a significantly lower rate of hospitalization requiring urgent revascularization, with no difference in death or myocardial infarction. In this substudy of the FAME 2 Trial, we evaluate the economic and quality-of-life implications of performing PCI in patients with stable coronary artery disease and an abnormal fractional flow reserve. We found significantly higher costs in the PCI arm at baseline, primarily attributable to drug-eluting stents. During follow-up, the cost difference between the 2 groups narrowed significantly, primarily because of the increased costs in the medical therapy arm from revascularization. The PCI patients had an immediate and significant improvement in quality of life. Assuming the initial difference in utility between the 2 groups gradually narrowed over 3 years, and assuming the difference in costs at 1 year did not change, the incremental cost-effectiveness ratio of PCI was $36 000 per quality-adjusted life-year. These findings were robust in bootstrap replications and sensitivity analyses. PCI of coronary lesions with reduced fractional flow reserve improves outcomes and appears economically attractive compared with best medical therapy among patients with stable angina. See p 1335.
Long-Term Effects of Secondary Prevention on Cognitive Function in Stroke Patients
The prevalence of cognitive impairment in patients with previous stroke is high, with up to a quarter of patients affected. The cognitive impairment is due at least in part to progressive ischemic damage occurring after the index event, so it seems logical that secondary prevention measures will reduce not only the risk of recurrent ischemic episodes but also the risk of global cognitive decline. This study shows that treating with antihypertensive medication or a combination of aspirin and dipyridamole significantly protects against cognitive decline. The combination of antihypertensives, antithrombotics, and lipid-lowering drugs reduces the risk of cognitive impairment by about half. The protective effect was not seen in hemorrhagic stroke patients or in patients whose stroke was associated with atrial fibrillation. See p 1341.
Systemic Hypertension in Low-Gradient Severe Aortic Stenosis With Preserved Ejection Fraction
Low-flow, low-gradient severe aortic stenosis with preserved ejection fraction is an increasingly recognized entity with discordant aortic stenosis severity criteria. Although treatment is controversial, it is generally recommended that such patients undergo aortic valve replacement when symptomatic and no other cause is found for symptoms. Systemic hypertension frequently coexists in this patient population, and the increased arterial afterload may itself cause elevated left ventricular filling pressures, which could play a major role in producing symptoms of dyspnea. In this study, symptomatic patients with hypertension (aortic systolic pressure >140 mm Hg) and low-gradient (mean gradient <40 mm Hg) severe aortic stenosis (aortic valve area <1 
Transforming Growth Factor-β Signaling Promotes Pulmonary Hypertension Caused by Schistosoma Mansoni
One of the most common causes of pulmonary arterial hypertension worldwide is infection with Schistosoma, the parasite that causes schistosomiasis, but how this infection results in pulmonary vascular disease is unknown. We developed an animal model of this disease by exposing mice to Schistosoma eggs, which recapitulates several key aspects of the human pathology, including elevated right ventricular pressures and pulmonary vascular remodeling. We observed an increase in the cytokine transforming growth factor-β1 (TGF-β1) after exposing the mice to Schistosoma, along with an increase in the TGF-β signaling mediator phospho-Smad2/3, and an increase in phospho-Smad2/3 was seen in the lung tissue of patients who died of this condition in Brazil. When we blocked TGF-β signaling in our animal model at the level of the TGF-β ligand using a neutralizing antibody, at the level of the receptor using small-molecule inhibitors, or at the level of intracellular signaling using Smad3 knockout mice, we prevented pulmonary hypertension. We thus suspect that the vascular remodeling in human schistosomiasis-associated pulmonary arterial hypertension and possibly other inflammatory forms of pulmonary arterial hypertension such as idiopathic disease or connective tissue-associated disease may be mediated by TGF-β, and targeting TGF-β signaling in the lung blood vessels may be of benefit for patients with this condition. See p 1354.
